Sanofi (SNY) Stock

NASDAQ
HealthcareDrug Manufacturers - General Website

SNY has an Alpha Score of 48 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 19 trades in SNY since 2017: 9 purchases and 10 sales, most recently Alan Armstrong (purchase, Mar 30, 2026). 5 of the hedge funds AlphaScala tracks reported SNY in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Millennium Management's at $230.73M. Its trailing P/E ratio is 14.8 and its net margin 10.9% (key statistics as of Nov 12, 2026).

$46.52
+1.00%
Last price
Source: Finnhub
Alpha Score
48
Weak

What is SNY's Alpha Score?

How it works →

Alpha Score of 48 reflects weak overall profile with weak momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
45
Weak
Value
70
Moderate
Quality
47
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Sanofi (SNY)?

Members
10
Disclosed trades
19
Purchases
9
Sales
10

Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Mar 16, 2017.

PoliticianTrade dateTypeAmount
Alan Armstrong
R-OK · Senate
2026-03-30purchase$15k – $50k
Lisa McClain
R-MI · House
2025-09-11sale$1k – $15k
Lisa McClain
R-MI · House
2025-08-04purchase$1k – $15k
Lisa McClain
R-MI · House
2025-07-22sale$1k – $15k
Lisa McClain
R-MI · House
2025-06-17purchase$1k – $15k
John James
R-MI · House
2024-09-04sale$1k – $15k
John James
R-MI · House
2023-11-10purchase$1k – $15k
Dan Goldman
D-NY · House
2023-07-10sale$15k – $50k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

See all SNY political trades →

Which hedge funds own SNY?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Millennium Management
Israel Englander
5.60M$230.73M+50%
Point72
Steve Cohen
2.66M$109.79M+225%
Citadel
Ken Griffin
751K$30.95M-59%
Bridgewater Associates
Ray Dalio
428K$17.66M+107%
Maverick Capital
Lee Ainslie
102K$4.21M+98%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

What are SNY's key statistics?

P/E Ratio
14.77
EPS (TTM)
5.78
Dividend Yield
4.12%
Beta
0.59
Net Margin
10.88%
ROE
9.81%
Debt / Equity
0.28
52W High
$90.07
52W Low
$69.75

Key statistics as of Nov 12, 2026

How does SNY's valuation compare with the Healthcare sector?

MetricSNYHealthcare medianCompanies in median
P/E ratio14.828.8145
Net margin10.88%3.62%218
Return on equity9.81%3.50%249
Dividend yield (payers)4.12%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.

What moved SNY recently?

AI-written from the data on this page

Sanofi flat as EPS decline and 52W low weigh on value score

Sanofi shares edged up 0.04% to $48.39 on Monday, holding near the bottom of a 52-week range that stretches from $69.75 to $90.07. The stock has shed roughly 30% from its high, with the P/E compressing to 14.77 on trailing earnings of $5.78 per share. Revenue grew 13.4% year over year, but EPS fell 55.6%, dragging net margin to 10.9%. The Alpha Score of 45.8 reflects a split profile: value scores 59.8 and momentum 50.6, while quality sits at 42.1. The EPS decline, driven by a high base effect from prior-year one-time gains, has overshadowed top-line growth. The next catalyst is the Q4 earnings report, due in early February, where investors will look for margin stabilization and an update on the pipeline.

SNY price chart

Powered by TradingView

What does Sanofi do?

Sanofi American Depositary Receipt represents American Depositary Shares (ADS) of Sanofi, a leading French multinational pharmaceutical company. Each ADR corresponds to one-half of an ordinary share listed on Euronext Paris, providing U.S. investors convenient access to the company's equity through a sponsored Level II ADR program managed by J.P. Morgan Chase Bank as depositary, with EQ Shareowner Services as transfer agent. Sanofi focuses on researching, developing, manufacturing, and marketing a broad portfolio of prescription medicines, vaccines, and consumer healthcare products addressing major unmet medical needs in areas such as immunology, neurology, oncology, cardiovascular diseases, and rare diseases. The ADR program ensures holders receive dividends in U.S. dollars, with options for reinvestment, and voting rights at the annual general meeting. Founded in 1973 and headquartered in Paris, France, Sanofi American Depositary Receipt facilitates seamless participation for U.S. shareholders in this global biopharmaceutical leader's ongoing innovations and market presence.

CEO
Mr. Olivier Charmeil
Employees
74,846
Market Cap
$103.10B
Ask about SNYAI research agent